🧬 For twenty years, the same worry has trailed iPS cell therapy like a shadow: put reprogrammed, "can-become-anything" cells into a human body, and might they grow into something no one can control? A team at Tokyo's Keio University just published the longest human answer yet. Four people with the most severe spinal cord injuries, followed for as long as four years after receiving iPS-derived cells. No tumors. No serious harm.

Four patients, four years, and the result they were waiting for

On July 21, neuroscientist Hideyuki Okano and orthopedic surgeon Masaya Nakamura reported that their first-in-human study had cleared its long-term safety checkpoint. Between 2020 and 2025, their team transplanted about two million neural precursor cells (young cells already committed to becoming nerve tissue) into four patients who had suffered complete spinal cord injuries. Each transplant happened within two to four weeks of the injury, a window doctors call the subacute phase. The cells came from a clinical-grade iPS cell line held in Kyoto University's cell stock.

Then they waited, and watched, for two to four years.

Across that span, the researchers found no tumor formation, no serious adverse events, and no clear worsening of neurological function. On the effect side, which the team keeps carefully separate from safety, a re-analysis of the one-year data showed all four patients had gained some limb strength, and two of them, starting from a state of no voluntary movement at all, recovered enough to move some muscles below the level of their injury. One had earlier been reported as able to stand and begin gait training. With only four patients, the team stresses, this is a hint of benefit, not proof. Proof requires a proper trial.

Why "no tumor" is the whole story

To a general reader, "no tumors after four years" can sound like a footnote. It is closer to the main event.

iPS cells earned Shinya Yamanaka a Nobel Prize in 2012 precisely because they can turn into almost any cell in the body. That same open-ended potential is the risk: cells that haven't fully committed, or a few stragglers that slip past quality control, can in principle keep dividing and form a growth. That fear has shadowed iPS clinical programs since the technology appeared, and Okano's own lab published on that exact oncogenic risk a decade ago. Short follow-ups can miss a slow-forming tumor. Four years of clean results in living patients is the kind of evidence that lets regulators, and the next set of patients, exhale a little.

The handoff, and a filing due next year

Safety established, the project now changes hands. K Pharma, a Keio spinout where Okano sits on the board, will run the next stage as a corporate clinical trial designed to test whether the cells actually restore function. The company says it aims to file a clinical trial notification with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) during the next fiscal year, which runs from April 2027 to March 2028. A notification is not approval; it starts the regulator's clock. But it moves the work from "a university proved this is safe" toward "a company is trying to prove it works."

The American version of this race, and why it stalled

In the United States, the flagship spinal cord cell therapy is OPC1, a product with a long and bruising history. It began at Geron, whose 22,000-page application, filed in 2008, made it the first sponsor the FDA cleared to test cells derived from human pluripotent stem cells (embryonic stem cells, not iPS, in this case). The first patient was dosed in 2010. Then, after treating just five of a planned ten, Geron shut the program down in 2011. The reason was money, not safety. The assets passed to Asterias, then to Lineage Cell Therapeutics, which restarted the work and in early 2025 launched a new FDA-cleared study enrolling both recent and long-standing injuries. OPC1 carries the FDA's fast-track "regenerative medicine advanced therapy" (RMAT) label. Eighteen years after that first filing, it remains an early-stage program.

Europe runs a different track again: cell therapies are regulated centrally as "advanced therapy medicinal products," with a priority-support scheme for promising candidates but a high bar of evidence before anything reaches the market.

The difference isn't carelessness versus caution. It's where each system places the finish line.

Japan's shortcut, and its price

Japan built its lead deliberately. In 2014 it created a "conditional and time-limited approval" route for regenerative products: show safety and a reasonable signal of benefit in a small group, and a therapy can reach patients provisionally, with up to seven years to gather the confirming data. A separate "Sakigake" designation fast-tracks review of home-grown breakthroughs. This is why 2026 saw the world's first approvals of iPS-derived regenerative products, both in Japan (a Parkinson's cell therapy and a heart-failure cell sheet), while other countries were still deep in trials.

The model has real critics, who argue the evidence bar can sit too low. Japan's own system has pushed back on that: in 2024, the very first product ever approved under the scheme, a heart-failure cell sheet, failed to prove its benefit in post-market data, was denied full approval and pulled from the market. That is the system working as designed. The spinal cord work isn't on that conditional track yet; it still has to earn its trial. But it is being built on the same foundation that keeps letting Japanese regenerative medicine reach the clinic first.

In Japan, a paralyzing injury once considered beyond repair now has four people, four years of safety data, and a company filing paperwork. How far has regenerative medicine for spinal cord injury gotten where you live, and if a trial like this opened tomorrow, would patients near you have a real way in?

References